Scarica l'app Stockscreener
2.52
5.26%
-0.14
Pre-mercato:
2.52
Ac Immune Sa Borsa (ACIU) Ultime notizie
AC Immune Parkinson’s Vaccine Study Meets Safety, Immunogenicity Goals - MarketBeat
AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions (NASDAQ:ACIU) - Seeking Alpha
H.C. Wainwright reiterates AC Immune stock rating on trial data By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates AC Immune stock rating on trial data - Investing.com
Top Penny Stocks To Watch In September 2026 - simplywall.st
AC Immune says ACI-7104 shows durable immunogenicity - thepharmaletter.com
AC Immune SA (ACIU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
AC Immune Says Investigational Parkinson’s Drug Shows 100% Antibody Response - benzinga.com
ACIU Looks 35.6% Undervalued on GF Value™ Despite Challenging Fu - GuruFocus
AC Immune reports positive phase 2 trial results for ACI-7104 - Investing.com Canada
AC Immune posts trial data for Parkinson’s drug (ACIU:NASDAQ) - Seeking Alpha
AC Immune Posts Strong Week-100 Phase 2 Data for Parkinson’s Vaccine ACI-7104 - TipRanks
AC Immune reports positive phase 2 trial results for Parkinson’s drug - Investing.com
Experimental Parkinson’s treatment from AC Immune (NASDAQ: ACIU) sparks immune response in early trial - Stock Titan
After 100 weeks, AC Immune's Parkinson's trial met its main safety and immune-response goals. - Stock Titan
AC Immune SA Share PriceACIU, RNS News, Articles, Quotes, & Charts (NASDAQ:ACIU) - Proactive financial news
AC Immune (ACIU) Slips 1.49% to $2.64 as Shares Sit Midway Between Key LevelsBlue Chip Entry Points - dars.gov.et
AC Immune’s New Phase 1 NLRP3 Trial Puts Inflammation Strategy in Focus - TipRanks
AC Immune SA (NASDAQ: ACIU) Schedules October 2 Vote for Tom Graney's Board Nomination - Kalkine Media
AC Immune Calls October EGM to Add Veteran Biopharma Financier Tom Graney to Board - TipRanks
Parkinson's drug Fast Tracked as AC Immune (NASDAQ: ACIU) plans board changes - stocktitan.net
AC Immune Ltd (NASDAQ: ACIU) Share Price, ACIU Stock News, ACIU Share Price & Updates - kalkine.ca
AC Immune2026 Funding Rounds & List of Investors - Tracxn
AC Immune reports positive phase 1 data for ACI‑19764 - PharmaTimes
AC Immune stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Positive Ph1 results for AC Immune's NLRP3 inflammasome inhibitor - pharmaphorum
AC (ACIU) Financial Update: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Market Price Moves 2.33% Higher on the DayConsensus Forecast Report - vinanet.vn
AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline - Benzinga
ACIU Reiterated by BTIG -- Price Target Maintained at $8.00 - GuruFocus
AC Immune's NLRP3 inhibitor reaches brain with safety intact in first human study - AllSci
AC Immune shares rise after encouraging early Phase 1 data for ACI-19764 - Yahoo Finance
AC Immune stock gains on early Phase 1 trial results - Investing.com India
AC Immune stock gains on early Phase 1 trial results By Investing.com - Investing.com Australia
AC Immune posts trial data for inflammatory drug (ACIU:NASDAQ) - Seeking Alpha
AC Immune reports phase 1 safety data for NLRP3 inhibitor By Investing.com - Investing.com Nigeria
AC Immune posts positive first‑in‑human data for NLRP3 inhibitor ACI‑19764 - TipRanks
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 - The Manila Times
AC Immune (NASDAQ: ACIU) advances NLRP3 pill into heart-risk trial - Stock Titan
AC (ACIU) Levels: Advances 0.39% to $2.58 in the Latest Reading; Chart View: $2.45 and $2.71 Define the Nearby Reference LevelsInside Day Breakout - vinanet.vn
AC Immune takes Parkinson's vaccine into US trials as Phase II data near - AllSci
ACIU Q2 2026 Earnings: Surprise EPS Beat of 117.61% Offers Little Support as Shares Slip 1.91%Quarterly Financial Update - careplusvn.com
ACIU Looks 33.6% Undervalued on GF Value™ Despite Financial Chal - GuruFocus
AC Immune receives FDA fast track status for parkinson’s drug By Investing.com - Investing.com Nigeria
AC Immune Wins FDA Fast Track for ACI-7104 in Early Parkinson’s Disease - TipRanks
AC Immune receives FDA fast track status for parkinson’s drug - Investing.com
AC Immune (NASDAQ: ACIU) gains FDA Fast Track, IND clearance for Parkinson’s drug ACI-7104 - Stock Titan
AC Immune’s Parkinson’s Candidate Shows 100% Responder Rate - Stock Titan
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):